• 1
    Ersboll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol. 1985; 35: 487496.
  • 2
    Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol. 1990; 8: 141145.
  • 3
    The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982; 49: 21122135.
  • 4
    van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998; 91: 11781184.
  • 5
    Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna Experience. Leuk Lymph. 1999; 32: 571576.
  • 6
    Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Ann Oncol. 1998; 9: 191194.
  • 7
    Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients. Ann Oncol. 2000; 11: 685690.
  • 8
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging. Cancer Res. 1971; 31: 18601861.
  • 9
    Tomita N, Kodama F, Sakai R, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymph. 2000; 38: 335343.
  • 10
    Tomita N, Kodama F, Kanamori H, et al. Treatment outcome in elderly patients with aggressive non-Hodgkin's lymphoma. Jpn J Clin Hematol. 2000; 41: 568575.
  • 11
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987994.
  • 12
    Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2: 12811288.
  • 13
    Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin's lymphoma: a single-center study of 532 patients. Arch Neurol. 1997; 54: 854859.